<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585908</url>
  </required_header>
  <id_info>
    <org_study_id>Doing-001</org_study_id>
    <nct_id>NCT02585908</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of γδ T Cell Against Gastric Cancer</brief_title>
  <official_title>γδ T Cell Immunotherapy for Treatment of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Doing Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Doing Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, safety and effects of γδT cells on human gastric cancer are going to be
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PBMC of the patient will be separated from peripheral blood. After making them potential
      cancer killer γδ T Cell and CIK, they will be infused to the patients as immunotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced size of the tumor.</measure>
    <time_frame>up to one year</time_frame>
    <description>Tumor load will be evaluated by RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, as measured by the rate of adverse events and serious adverse events</measure>
    <time_frame>up to two years</time_frame>
    <description>Safety, as measured by the rate of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Group A(control group)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular treatment and follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIK will be used against tumor cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>γδ T will be used against tumor cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIK and γδ T will be used against tumor cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <description>CIK cells will be used against tumor cells.</description>
    <arm_group_label>Experimental Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>γδ T</intervention_name>
    <description>γδ T cells will be used against tumor cells.</description>
    <arm_group_label>Experimental Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK and γδ T</intervention_name>
    <description>CIK and γδ T cells will be used against tumor cells.</description>
    <arm_group_label>Experimental Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:30-75

          2. Karnofsky performance status &gt;50

          3. Diagnosis with gastric cancer based on histology or the current accepted radiological
             measures.

          4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ

          5. Patients who have a life expectancy of at least 12 weeks

          6. Ability to understand the study protocol and a willingness to sign a written informed
             consent document

        Exclusion Criteria:

          1. Any significant medical or psychiatric illness that would prevent the patient from
             giving informed consent or from following the study procedures.

          2. Known human immunodeficiency virus (HIV) infection.

          3. Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic
             infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV)
             infection).

          4. Other serious underlying medical conditions, which, in the Investigator's judgment,
             could impair the ability of the patient.

          5. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li gangyi, master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Doing Biomedical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xie yanyun, master</last_name>
    <phone>086-15601041145</phone>
    <email>yanyun_xie@doingtimes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>li gangyi, master</last_name>
    <phone>086-13901106501</phone>
    <email>gangyi_li@doingtimes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huai'An First People'S Hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

